Accustem Sciences Inc. (ACUT) Form 10-Q — May 15, 2026
AccuStem Sciences Inc. reported a net loss of $485,883 for the quarter ended March 31, 2026, driven by increased R&D expenses of $119,525 for its MSC and StemPrintER diagnostic tests. The company has no revenue and holds only $12,207 in cash against total liabilities of $5.4 million, including a $4.7 million payable to related party Tiziana. Management disclosed a material weakness in internal controls over financial reporting due to a lack of accounting resources and inadequate segregation of duties.
Key figures
- Revenue
- 0
- Total Debt
- 5421879
- Total Assets
- 1549532
- Cash Position
- 12207
- Shares Outstanding
- 16072267
- Rd expenses q1 2026
- 119525
- G a expenses q1 2026
- 366358
- Related party payable
- 4682455
- Unrecognized compensation expense
- 436360
Price after filing
Close on the filing date to close N calendar days later (from $0.26). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.